Provention Bio, Inc. today announced that the resubmitted Biologics License Application (BLA) for teplizumab for the delay of clinical type 1 diabetes (T1D) in at-risk individuals has been considered a complete, class 2 response to the July 2021 action letter by the U.S. Food and Drug Administration (FDA). The FDA has assigned a user fee…
БҰЛ МАҚАЛАДАН НЕ АЛУ КЕРЕК:
- today announced that the resubmitted Biologics License Application (BLA) for teplizumab for the delay of clinical type 1 diabetes (T1D) in at-risk individuals has been considered a complete, class 2 response to the July 2021 action letter by the U.
- Бұл мазмұн тек ТЕГІН ЖАЗЫЛУ мүшелеріне арналған.
- Азық-түлік және дәрі-дәрмек басқармасы (FDA).
